Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.

doi:10.1111/j.1442-2042.2005.01004.x

Article

Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.

International journal of urology : official journal of the Japanese Urological Association - 1 Feb 2005

Suzuki Motofumi, Muto Satoru, Hara Kazuo, Ozeki Takeshi, Yamada Yasuhiko, Kadowaki Takashi, Tomita Kyoichi, Kameyama Shuji, Kitamura Tadaichi

Abstract excerpt

BACKGROUND: Estramustine phosphate sodium (EMP) frequently causes side-effects such as gastrointestinal discomfort, nausea, and edema in extremities. We analyzed single nucleotide polymorphisms (SNP) in the 17beta-hydroxysteroid dehydrogenase (HSD17B) genes, which are involved in the metabolism of EMP, to predict the risk of EMP side-effects in prostate cancer patients. METHODS: We performed genotyping of SNP in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Single-nucleotide polymorphisms in the 17beta-hydroxysteroid dehydrogenase genes might predict the risk of side-effects of estramustine phosphate sodium in prostate cancer patients.

Abstract excerpt

Topics

Related research